295 related articles for article (PubMed ID: 31694133)
1. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
2. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
3. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
4. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
6. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
7. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
[TBL] [Abstract][Full Text] [Related]
8. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
10. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
[TBL] [Abstract][Full Text] [Related]
12. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study.
Ishizawa T; Makino N; Matsuda A; Kakizaki Y; Kobayashi T; Ikeda C; Sugahara S; Tsunoda M; Ueno Y
PLoS One; 2020; 15(1):e0228565. PubMed ID: 31999789
[TBL] [Abstract][Full Text] [Related]
14. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma.
Kawesha A; Ghaneh P; Andrén-Sandberg A; Ograed D; Skar R; Dawiskiba S; Evans JD; Campbell F; Lemoine N; Neoptolemos JP
Int J Cancer; 2000 Nov; 89(6):469-74. PubMed ID: 11102889
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9.
Ono M; Ono Y; Nakamura T; Tsuchikawa T; Kuraya T; Kuwabara S; Nakanishi Y; Asano T; Matsui A; Tanaka K; Ebihara Y; Kurashima Y; Noji T; Murakami S; Shichinohe T; Mitsuhashi T; Omori Y; Furukawa T; Taniue K; Suzuki M; Sugitani A; Karasaki H; Mizukami Y; Hirano S
Ann Surg Oncol; 2022 Aug; 29(8):5007-5019. PubMed ID: 35399143
[TBL] [Abstract][Full Text] [Related]
16. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
17. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
Salek C; Benesova L; Zavoral M; Nosek V; Kasperova L; Ryska M; Strnad R; Traboulsi E; Minarik M
World J Gastroenterol; 2007 Jul; 13(27):3714-20. PubMed ID: 17659731
[TBL] [Abstract][Full Text] [Related]
19. [Will molecular diagnostics become established in pancreatic pathology?].
Sipos B; Sperveslage J
Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
